Menopause, immunity, and autoimmune rheumatic diseases – pathogenetic intersections and clinical implications

Literature review

Authors

DOI:

https://doi.org/10.18370/2309-4117.2026.82.74-82

Keywords:

menopause, autoimmune diseases, rheumatic diseases, estrogens, immunosenescence, immune regulation

Abstract

Menopause is a physiological stage in a woman’s life characterized by permanent ovarian failure and sustained estrogen deficiency, leading to systemic endocrine, metabolic, and immunological changes. Declining estrogen levels are associated with the development of a pro-inflammatory immune phenotype, immunosenescence, and disruption of the delicate balance between innate and adaptive immunity. These mechanisms are highly relevant to autoimmune and rheumatic diseases, as menopause may modify disease expression, clinical manifestations, and long-term complications rather than acting solely as a chronological event.

Estrogens play a central role in regulating macrophage function, T- and B-cell responses, cytokine production, and immune tolerance. Estrogen deficiency promotes a shift toward Th1- and Th17-driven immune responses, reduction of regulatory T cells, and enhanced activity of pro-inflammatory mediators. In parallel, age-related immune remodeling, including epigenetic alterations, may further amplify chronic inflammation and contribute to cumulative organ damage.

In patients with rheumatoid arthritis and systemic scleroderma, menopause is more often associated with poorer functional outcomes and an increased risk of vascular complications, whereas postmenopausal lupus erythematosus usually has a milder clinical course. Sjögren’s disease has a peak incidence in the perimenopause, indicating a significant role for estrogen deficiency in exocrine gland damage.

Menopause also has a profound impact on the musculoskeletal system, accelerating bone loss and increasing the risk of osteoporosis and fragility fractures, particularly in women with chronic inflammatory conditions. These effects result from the combined influence of estrogen deficiency, immune dysregulation, and persistent low-grade inflammation.

Menopausal hormone therapy may be considered in patients with rheumatic diseases to alleviate symptoms related to estrogen deficiency within an individualized risk–benefit framework. In particular, menopausal hormone therapy helps reduce musculoskeletal pain, improve a woman’s well-being and quality of life, alleviate urogenital symptoms in patients with Sjögren’s disease, and reduces the frequency of exacerbations and the risk of developing ACPA-positive rheumatoid arthritis.

Author Biographies

Y.D. Yehudina, Clinic of Modern Rheumatology, Kyiv

MD, professor

S.А. Trypilka, Medical Center «Health», Kharkiv

PhD, associate professor, rheumatologist

References

  1. Hall JE. Endocrinology of the menopause. Endocrinol Metab Clin North Am 2015;44(3):485–96. DOI: 10.1016/j.ecl.2015.05.001
  2. Ye L, Knox B, Hickey M. Management of menopause symptoms and quality of life during the menopause transition. Endocrinol Metab Clin North Am 2022;51(4):817–36. DOI: 10.1016/j.ecl.2022.04.006
  3. Wright VJ, Schwartzman JD, Itinoche R, Wittstein J. The musculoskeletal syndrome of menopause. Climacteric 2024;27(5):466–472. DOI: 10.1080/13697137.2024.2380363
  4. Gulati M, Dursun E, Vincent K, Watt FE. The influence of sex hormones on musculoskeletal pain and osteoarthritis. Lancet Rheumatol 2023;5(4):e225–38. DOI: 10.1016/S2665-9913(23)00060-7.
  5. Motta F, Barone E, Sica A, Selmi C. Inflammaging and osteoarthritis. Clin Rev Allergy Immunol 2023;64(2):222–38. DOI: 10.1007/s12016-022-08941-1.
  6. Kim YR, Jung Y, Kang I, Yeo EJ. Understanding sex differences in autoimmune diseases: Immunologic mechanisms. Int J Mol Sci 2025;26(15):7101. DOI: 10.3390/ijms26157101
  7. Ortona E, Pierdominici M, Maselli A, Veroni C, Aloisi F, Shoenfeld Y. Sex-based differences in autoimmune diseases. Ann Ist Super Sanita 2016;52(2):205–12. DOI: 10.4415/ANN_16_02_12
  8. Han A, Kim JY, Kwak-Kim J, Lee SK. Menopause is an inflection point of age-related immune changes in women. J Reprod Immunol 2021;146:103346.DOI: 10.1016/j.jri.2021.103346
  9. Zhang C, Yu D, Mei Y, Liu S, Shao H, Sun Q, et al. Single-cell RNA sequencing of peripheral blood reveals immune cell dysfunction in premature ovarian insufficiency. Front Endocrinol (Lausanne) 2023;14:1129657. DOI: 10.3389/fendo.2023.1129657
  10. Hamoda H, Sharma A. Premature ovarian insufficiency, early menopause, and induced menopause. Best Pract Res Clin Endocrinol Metab 2024;38(1):101823. DOI: 10.1016/j.beem.2023.101823
  11. Sharif K, Watad A, Bridgewood C, Kanduc D, Amital H, Shoenfeld Y. Insights into the autoimmune aspect of premature ovarian insufficiency. Best Pract Res Clin Endocrinol Metab 2019;33(6):101323. DOI: 10.1016/j.beem.2019.101323
  12. Grossmann B, Saur S, Rall K, Pecher AC, Hübner S, Henes J, et al. Prevalence of autoimmune disease in women with premature ovarian failure. Eur J Contracept Reprod Health Care 2020;25(1):72–75. DOI: 10.1080/13625187.2019.1702638
  13. Sciarra F, Campolo F, Franceschini E, Carlomagno F, Venneri MA. Gender-specific impact of sex hormones on the immune system. Int J Mol Sci 2023;24(7):6302. DOI: 10.3390/ijms24076302
  14. Xiang X, Palasuberniam P, Pare R. The Role of Estrogen across Multiple Disease Mechanisms. Curr Issues Mol Biol 2024;46(8):8170–8196. DOI:10.3390/cimb46080483
  15. Merrheim J, Villegas J, Van Wassenhove J, Khansa R, Berrih-Aknin S, le Panse R, et al. Estrogen, estrogen-like molecules and autoimmune diseases. Autoimmunity Reviews 2020;19(3):102468. DOI:10.1016/j.autrev.2020.102468
  16. Gubbels Bupp MR. Sex, the aging immune system, and chronic disease. Cell Immunol 2015;294(2):102–10. DOI: 10.1016/j.cellimm.2015.02.002
  17. Chakraborty B, Byemerwa J, Krebs T, Lim F, Chang CY, McDonnell DP. Estrogen receptor signaling in the immune system. Endocr Rev 2023;44(1):117–41. DOI: 10.1210/endrev/bnac017
  18. Zhou M, Shu Y, Gao J. Thymus Degeneration in Women and the Influence of Female Sexual Hormones on Thymic Epithelial Cells. Int J Mol Sci 2025;26(7):3014. DOI:10.3390/ijms26073014
  19. Asaba J, Bandyopadhyay M, Kindy M, Dasgupta S. Estrogen receptor signal in regulation of B cell activation during diverse immune responses. Int J Biochem Cell Biol 2015;68:42–7. DOI: 10.1016/j.biocel.2015.08.012
  20. Cheng CH, Chen LR, Chen KH. Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci 2022;23(3):1376. DOI: 10.3390/ijms23031376
  21. Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell Immunol 2015;294(2):63–9. : 10.1016/j.cellimm.2015.01.018
  22. Bleve A, Motta F, Durante B, Pandolfo C, Selmi C, Sica A. Immunosenescence, inflammaging, and frailty: role of myeloid cells in age-related diseases. Clin Rev Allergy Immunol 2023;64(2):123–44. DOI: 10.1007/s12016-022-08909-7
  23. Hedrich CM. Mechanistic aspects of epigenetic dysregulation in SLE. Clin Immunol 2018;196:3–11. DOI: 10.1016/j.clim.2018.02.002
  24. Desai MK, Brinton RD. Autoimmune disease in women: endocrine transition and risk across the lifespan. Front Endocrinol (Lausanne) 2019;10:265. DOI: 10.3389/fendo.2019.00265
  25. Khalaf MS, Hussein WN. Pro-inflammatory cytokines and insulin resistance in postmenopausal women with central obesity: A cross-sectional analytical study. Regulatory Mechanisms in Biosystems 2025;16(3). DOI: 10.15421/0225147
  26. Chen Y, Zhang Y, Zhao G, Chen C, Yang P, Ye S, et al. Difference in leukocyte composition between women before and after menopausal age, and distinct sexual dimorphism. PLoS ONE 2016;11(9):e0162953. DOI: 10.1371/journal.pone.0162953
  27. Güngör Çakır AN, Candevir A. Review on Menopause and Immunity. Archive Source Review Journal 2025;34(2):156–161. DOI: 10.17827/aktd.1637408
  28. Sapir-Koren R, Livshits G. Rheumatoid arthritis onset in postmenopausal women: does the ACPA seropositive subset result from genetic effects, estrogen deficiency, skewed profile of CD4(+) T-cells, and their interactions? Mol Cell Endocrinol 2016;431:145–63. DOI: 10.1016/j.mce.2016.05.009
  29. Christensen AO, Li G, Young CH, Snow B, Khan SA, DeVore SB, et al. Peptidylarginine deiminase enzymes and citrullinated proteins in female reproductive physiology and associated diseases. Biol Reprod 2022;107(6):1395–410. DOI: 10.1093/biolre/ioac173
  30. Engdahl C, Bondt A, Harre U, Raufer J, Pfeifle R, Camponeschi A, et al. Estrogen induces St6gal1 expression and increases IgG sialylation in mice and patients with rheumatoid arthritis: a potential explanation for the increased risk of rheumatoid arthritis in postmenopausal women. Arthritis Res Ther 2018;20(1):84. DOI: 10.1186/s13075-018-1586-z
  31. Alpizar-Rodriguez D, Mueller RB, Möller B, Dudler J, Ciurea A, Zufferey P, et al. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology (Oxford) 2017;56(9):1579–85. DOI: 10.1093/rheumatology/kex239
  32. Hoffmann JP, Liu JA, Seddu K, Klein SL. Sex hormone signaling and regulation of immune function. Immunity 2023;56(11):2472–2491. DOI: 10.1016/j.immuni.2023.10.008
  33. Dai X, Li P, Pan D. Research trends in estrogen and rheumatoid arthritis: a systematic bibliometric approach. Biol Sex Differ 2025. DOI: 10.1186/s13293-025-00806-4
  34. Cutolo M, Gotelli E. Complex role of oestrogens in the risk and severity of rheumatoid arthritis in menopause. RMD Open 2023;9(2):e003176. DOI: 10.1136/rmdopen-2023-003176
  35. Xiao Y, Yi Y, Jing D, Yang S, Guo Y, Xiao H, et al. Age at natural menopause, reproductive lifespan, and the risk of late-onset psoriasis and psoriatic arthritis in women: a prospective cohort study. J Invest Dermatol 2024;144(6):1273–81.e5. DOI: 10.1016/j.jid.2023.11.010
  36. Ivory C, Shamaa M, Alfuwayris J. Menopause symptom severity in systemic lupus erythematosus. J Rheumatol 2025;52(Suppl 1):160–161. DOI: 10.3899/jrheum.2025-0390.PV138
  37. Gompel A. Systemic lupus erythematosus and menopause. Climacteric 2020;23(2):109–115. DOI: 10.1080/13697137.2019.1679113
  38. Zhang J, Sun Q, Wang A, Pan M, Wu W, Lin Z, et al. The association between Sjogren’s disease and sex hormones: A case-control and Mendelian randomization study. SAGE Open Med 2025;13:20503121251405020. DOI: 10.1177/20503121251405020
  39. Xuan Y, Zhang X, Wu H. Impact of sex differences on the clinical presentation, pathogenesis, treatment and prognosis of Sjögren’s syndrome. Immunology 2024;171(4):513–24. DOI: 10.1111/imm.13740
  40. Talsania M, Scofield RH. Menopause and rheumatic disease. Rheum Dis Clin North Am 2017;43(2):287–302. DOI: 10.1016/j.rdc.2016.12.011
  41. Park EH, Kang EH, Lee YJ, Ha YJ. Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: a large observational cohort study of Korean patients with rheumatoid arthritis. RMD Open 2023;9(1):e002722. DOI: 10.1136/rmdopen-2022-002722
  42. Mollard E, Pedro S, Chakravarty E, Clowse M, Schumacher R, Michaud K. The impact of menopause on functional status in women with rheumatoid arthritis. Rheumatology (Oxford) 2018;57(5):798–802. DOI: 10.1093/rheumatology/kex526
  43. Alpizar-Rodriguez D, Förger F, Courvoisier DS, Gabay C, Finckh A. Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort. Rheumatology (Oxford) 2019;58(3):432–40. DOI: 10.1093/rheumatology/key311
  44. Benagiano G, Benagiano M, Bianchi P, D’Elios MM, Brosens I. Contraception in autoimmune diseases. Best Pract Res Clin Obstet Gynaecol 2019;60:111–23. DOI: 10.1016/j.bpobgyn.2019.05.003
  45. Orellana C, Saevarsdottir S, Klareskog L, Karlson EW, Alfredsson L, Bengtsson C. Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study. Eur J Epidemiol 2015;30(5):449–57. DOI: 10.1007/s10654-015-0014-y
  46. Jeong H, Bae EK, Hwang J, Park EJ, Lee J, Jeon CH, et al. The effects of sex and estrogen on radiographic progression of ankylosing spondylitis in Korean patients. J Rheum Dis 2021;28(2):76–84. DOI: 10.4078/jrd.2021.28.2.76
  47. Wu S, Cho E, Li W, Grodstein F, Qureshi AA. Hormonal factors and risk of psoriasis in women: a cohort study. Acta Derm Venereol 2016;96(7):927–31. DOI: 10.2340/00015555-2312
  48. Cassalia F, Lunardon A, Frattin G, Danese A, Caroppo F, Belloni Fortina A. How hormonal balance changes lives in women with psoriasis. J Clin Med 2025;14(2):582. DOI: 10.3390/jcm14020582
  49. Tsaliki M, Koelsch KA, Chambers A, Talsania M, Scofield RH, Chakravarty EF. Ovarian antibodies among SLE women with premature menopause after cyclophosphamide. Int J Rheum Dis 2021;24(1):120–124. DOI: 10.1111/1756-185X.14022
  50. Kim JW, Kim HA, Suh CH, Jung JY. Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus. Front Med (Lausanne) 2022;9:906475. DOI: 10.3389/fmed.2022.906475
  51. Khafagy AM, Stewart KI, Christianson MS, Tao Y, Blanck JF, Shen W. Effect of menopause hormone therapy on disease progression in systemic lupus erythematosus: a systematic review. Maturitas 2015;81(2):276–81. DOI: 10.1016/j.maturitas.2015.03.017
  52. Gomes LLAG, Werth AJ, Thomas P, Werth VP. The impact of hormones in autoimmune cutaneous diseases. J Dermatolog Treat 2024;35(1):2312241. DOI: 10.1080/09546634.2024.2312241
  53. Skare TL, Hauz E, de Carvalho JF. Dehydroepiandrosterone (DHEA) supplementation in rheumatic diseases: A systematic review. Mediterr J Rheumatol 2023;34(3):292–301. DOI: 10.31138/mjr.20230825.dd
  54. Kapoor E, Kling JM, Lobo AS, Faubion SS. Menopausal hormone therapy in women with medical conditions. Best Pract Res Clin Endocrinol Metab 2021;35(6):101578. DOI: 10.1016/j.beem.2021.101578
  55. Dai L, Xu D, Li X, Huang S, Duan X, Zheng A, et al. Reproductive health in female patients with systemic sclerosis: a cross-sectional study. Rheumatology (Oxford) 2023;63(7):1911–16. DOI: 10.1093/rheumatology/kead497
  56. Orlandi M, Giuggioli D, Ferri C, De Angelis R, Riccieri V, Cacciapaglia F, et al. Menopause in systemic sclerosis: the impact on clinical presentation in a multicenter cross-sectional analysis from the National Registry of the Italian Society for Rheumatology (SPRING-SIR). Ther Adv Musculoskelet Dis 2025;17:1759720X251354898. DOI: 10.1177/1759720X251354898
  57. Ciaffi J, van Leeuwen NM, Schoones JW, Huizinga TWJ, de Vries-Bouwstra JK. Sex hormones and sex hormone-targeting therapies in systemic sclerosis: A systematic literature review. Semin Arthritis Rheum 2020;50(1):140–148. DOI: 10.1016/j.semarthrit.2019.07.007
  58. Walker MD, Shane E. Postmenopausal osteoporosis. N Engl J Med 2023;389(21):1979–91. DOI: 10.1056/NEJMcp2307353.
  59. Buttgereit F, Palmowski A, Bond M, Adami G, Dejaco C. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol 2024;20(7):417–31. DOI: 10.1038/s41584-024-01120-w
  60. NAMS. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29:767–794. DOI: 10.1097/GME.0000000000002028.
  61. Bugatti S, Bogliolo L, Manzo A, De Stefano L, Delvino P, Motta F, et al. Impact of anti-citrullinated protein antibodies on progressive systemic bone mineral density loss in patients with early rheumatoid arthritis after two years of treat-to-target. Front Immunol 2021;12:701922. DOI: 10.3389/fimmu.2021.701922

Downloads

Published

2026-04-18

How to Cite

Yehudina, Y., & Trypilka, S. (2026). Menopause, immunity, and autoimmune rheumatic diseases – pathogenetic intersections and clinical implications: Literature review. REPRODUCTIVE ENDOCRINOLOGY, (82), 74–82. https://doi.org/10.18370/2309-4117.2026.82.74-82

Issue

No. 82 (2026)

Section

Interdisciplinary problems

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.